ISSN 0303-5212
 
2024, Vol: 49, Issue: 4
49 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Author_ Certificate.docx
Bank Reciept

Review Article 


Role of baricitinib and sotrovimab in the management of COVID-19

Darmadi Darmadi, Cennikon Pakpahan, Sem Samuel Surja.


Abstract
Objective: To review the role of baricitinib and sotrovimab in managing COVID-19, amidst evolving treatment guidelines and varying efficacy against different virus variants.
Methodology: This review utilized online database using specific keywords related to the subject independently performed with manual checks of reference lists for completeness.
Results: Baricitinib, authorized with remdesivir for severe COVID-19, reduces mechanical ventilation and ICU admissions without increasing hospital stays, and shows improved mortality and recovery rates, especially when combined with corticosteroids. Sotrovimab, effective in early clinical trials at reducing hospitalizations and adverse events, has shown comparable or superior efficacy to other antivirals but lost authorization for variants like Omicron BA.2.
Conclusion: Baricitinib works as a JAK inhibitor with a 2 mg dose recommended for COVID-19, while sotrovimab, a monoclonal antibody, neutralizes SARS-CoV-2 but has limitations against certain variants. Both drugs offer significant benefits in treating severe COVID-19.

Key words: Baricitinib, COVID-19, guideline, management, sotrovimab.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Darmadi Darmadi
Articles by Cennikon Pakpahan
Articles by Sem Samuel Surja
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Darmadi D, Pakpahan C, Surja SS. Role of baricitinib and sotrovimab in the management of COVID-19. RMJ. 2024; 49(3): 678-681. doi:10.5455/rmj.20240407084012

Web Style

Darmadi D, Pakpahan C, Surja SS. Role of baricitinib and sotrovimab in the management of COVID-19. https://www.rmj.org.pk/?mno=196956 [Access: November 17, 2024]. doi:10.5455/rmj.20240407084012

AMA (American Medical Association) Style

Darmadi D, Pakpahan C, Surja SS. Role of baricitinib and sotrovimab in the management of COVID-19. RMJ. 2024; 49(3): 678-681. doi:10.5455/rmj.20240407084012


Vancouver/ICMJE Style

Darmadi D, Pakpahan C, Surja SS. Role of baricitinib and sotrovimab in the management of COVID-19. RMJ. (2024), [cited November 17, 2024]; 49(3): 678-681. doi:10.5455/rmj.20240407084012


Harvard Style

Darmadi, D., Pakpahan, . C. & Surja, . S. S. (2024) Role of baricitinib and sotrovimab in the management of COVID-19. RMJ, 49 (3), 678-681. doi:10.5455/rmj.20240407084012


Turabian Style

Darmadi, Darmadi, Cennikon Pakpahan, and Sem Samuel Surja. 2024. Role of baricitinib and sotrovimab in the management of COVID-19. Rawal Medical Journal, 49 (3), 678-681. doi:10.5455/rmj.20240407084012


Chicago Style

Darmadi, Darmadi, Cennikon Pakpahan, and Sem Samuel Surja. "Role of baricitinib and sotrovimab in the management of COVID-19." Rawal Medical Journal 49 (2024), 678-681. doi:10.5455/rmj.20240407084012


MLA (The Modern Language Association) Style

Darmadi, Darmadi, Cennikon Pakpahan, and Sem Samuel Surja. "Role of baricitinib and sotrovimab in the management of COVID-19." Rawal Medical Journal 49.3 (2024), 678-681. Print. doi:10.5455/rmj.20240407084012


APA (American Psychological Association) Style

Darmadi, D., Pakpahan, . C. & Surja, . S. S. (2024) Role of baricitinib and sotrovimab in the management of COVID-19. Rawal Medical Journal, 49 (3), 678-681. doi:10.5455/rmj.20240407084012


Author LoginReviewer LoginEditorial PoliciesConflict of Interest PolicyPlagiarism PolicyAdvertising Policy

About Rawal Medical Journal

Publication, subscription and Editorial office PMA House G/220-B Liaquat Road, Rawalpindi. Phone: 051-555-9812, Fax: 051-553-7088 Email: drnkhokhar@ya ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information